On February 26, 2026, the South Korean pharmaceutical company Samchundang Pharmaceutical made headlines after its stock price soared to record highs on the Korea Exchange (KRX). The catalyst? A blockbuster deal with a global pharmaceutical company based in Europe, granting exclusive licensing and commercialization rights for Samchundang’s oral GLP-1 (semaglutide) generics—targeting diabetes and obesity—to 11 European countries, including the United Kingdom and the Netherlands.
According to Maeil Business Newspaper, at 11:38 AM KRX time, Samchundang’s stock had already climbed 22.13% to 712,000 KRW. By 1:34 PM, as reported by JoongAng Economy News and Seoul Economic Daily, it had surged to the daily upper limit, up 29.85% at 757,000 KRW. This meteoric rise propelled Samchundang to become the fourth-largest company by market capitalization on the KOSDAQ, overtaking well-known names like Rainbow Robotics and reaching a valuation of 17.7573 trillion KRW.
What’s behind this investor frenzy? The answer lies in the details of the newly inked agreement. Samchundang’s deal covers exclusive sales and product supply rights for its oral GLP-1 generics—specifically, versions of the diabetes drug Rybelsus and the obesity treatment Wegovy—for 11 European countries. The total contract value is a staggering 5.3 trillion KRW (roughly $4 billion USD), with Samchundang set to receive 30 million euros in upfront and milestone payments. But perhaps most eye-catching is the profit-sharing arrangement: despite the European market’s tender-based structure, Samchundang will retain a remarkable 60% of net sales profits.
Industry insiders are calling this profit split virtually unheard of. A company official, quoted by Maeil Business Newspaper, stated, “The countries involved in this contract operate on a government tender system. If patent circumvention and price competitiveness are secured, there’s a high chance of expanding market share. Even in a tender-based structure, securing 60% of net profits is an exceptional condition.”
Why did Samchundang secure such favorable terms? The answer lies in its proprietary SNAC-free formulation technology. The company claims this technology allows its generics to bypass the original formulation patents—often a significant hurdle in the pharmaceutical industry. Furthermore, partner audits have confirmed that Samchundang’s production costs are highly competitive, reportedly just 10% of the selling price. As one company representative explained, “Our SNAC-free formulation perfectly circumvents the original patent, and the partner’s audit confirmed our overwhelming cost competitiveness.”
This technological edge is especially significant given the European market’s current landscape. The semaglutide market in Europe is already valued at about 9 trillion KRW, according to Maeil Business Newspaper, even though Wegovy, the obesity treatment, is not yet approved in some countries and supply shortages persist. Despite these hurdles, the diabetes indication alone has created a multibillion-dollar market. Samchundang projects that, with continued annual growth rates of around 45%, the market could balloon to over 30 trillion KRW in the coming years.
“At the time of full-scale product launch, we expect the European semaglutide market to form a massive market exceeding 30 trillion KRW,” the company stated, as reported by JoongAng Economy News and Seoul Economic Daily. This optimism is echoed by analysts and investors alike, who see Samchundang’s early-mover advantage and patent-circumventing technology as key drivers for future growth.
Samchundang’s strategy for European expansion is notably methodical. The company has divided the continent into three distinct regions: government tender markets, private insurance markets, and Eastern Europe. The initial agreement secures entry into 11 countries, focusing primarily on those with government tender systems such as the UK and the Netherlands. However, Samchundang is not resting on its laurels. The company confirmed ongoing negotiations for additional contracts in major European Union markets, including Germany, France, Italy, and Spain. This phased approach is designed to maximize the company’s reach and tailor its strategy to the unique regulatory and market dynamics of each region.
Beyond the numbers and business strategy, the deal signals a new era for Samchundang’s global ambitions. The company’s ability to clinch such a lucrative and strategically significant contract is being touted as a sign of its readiness to become a major player on the international pharmaceutical stage. As Seoul Economic Daily put it, this agreement is “a signal flare for Samchundang’s full-scale global market domination.”
Of course, the pharmaceutical market is never without risk. The European market’s reliance on government tenders means that pricing pressure and competitive bidding are persistent challenges. However, Samchundang’s 60% net profit share—even in this environment—provides a strong buffer against margin erosion. Moreover, the company’s SNAC-free technology could set a new standard for patent circumvention in the generics space, potentially opening doors in other global markets where original formulation patents still pose barriers.
It’s also worth noting that, while the upfront payment of approximately 50.8 billion KRW is significant, the true value of the deal lies in the long-term profit-sharing arrangement. If Samchundang’s projections for market growth and penetration hold true, the company could be looking at sustained revenue streams for years to come.
The excitement around Samchundang’s stock is palpable, but company officials and financial news outlets alike have cautioned investors to approach with care. As Maeil Business Newspaper noted, “This article is for reference in investment decisions, and the publisher is not responsible for any investment losses based on this information.” Such warnings are standard, but they underscore the volatility that often accompanies major pharmaceutical breakthroughs and market entries.
In summary, Samchundang Pharmaceutical’s explosive stock performance on February 26, 2026, is the result of a landmark agreement that not only secures its entry into key European markets but also sets a new benchmark for profit-sharing in the generics industry. With its SNAC-free technology, aggressive market segmentation, and eye on further expansion, Samchundang is positioning itself at the forefront of a rapidly growing—and highly competitive—global market. Investors and industry watchers alike will be keeping a close eye on how this ambitious scenario unfolds in the months and years ahead.